newsfilter
← Latest News
GlobeNewswire·

Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update

- Partial clinical hold lifted by FDA on VGL101 - - Launched ALSPAware to provide access to no-cost genetic testing and counseling for ALSP - - Appointed distinguished biopharmaceutical industry leader, Samantha Budd